Indiana Medicaid Will Cover GLP-1s for Obesity
The state will pay $85.16 of the $245 monthly cost per person as manufacturers add free lifestyle support.
- On Thursday, Gov. Mike Braun directed the Indiana Family and Social Services Administration to join the federal BALANCE initiative, expanding GLP-1 obesity medication access to 1.9 million Hoosiers through Medicaid.
- A 2024 survey by the Centers for Disease Control and Prevention found 38% of Indiana adults are obese, while obesity costs the state an estimated $10.7 billion annually, nearly 2% of GDP.
- Under the BALANCE agreement, manufacturers will provide GLP-1s at $245 per person monthly; Indiana Medicaid pays $85.16, with federal funds and manufacturer discounts covering the remainder.
- Eli Lilly and Novo Nordisk are collaborating with the Centers for Medicare & Medicaid Innovation Center to make treatments like Zepbound and Foundayo more affordable for state Medicaid programs.
- While Indiana officials committed to the program, the agreement is currently being finalized, and specific eligibility criteria and implementation timelines will be released once the deal is complete.
15 Articles
15 Articles
What happens when insurance rejects prescribed care for hormone patients seeking GLP-1s
Puberty came for Jez Roberts early. The hormones, which often made her menstrual cycles incredibly painful, never let up. Even at the age of 10, when she first got her period, she knew something wasn’t right. With each passing year, her menstrual cycle worsened. So did the pain. It would take 14 years for her to be diagnosed with polyendocrine metabolic ovarian syndrome, or PMOS, a hormonal disorder formerly known as PCOS, that affects 10% of…
Terre Haute Tribune-Star
Louisville Public MediaIndiana expands access to GLP-1s for Medicaid recipients with obesity
Indiana is expanding access to GLP-1s — the diabetes and weight loss medications — to members of the state’s Medicaid program.
Indiana Medicaid will cover GLP-1s for obesity - The Mexico Ledger
Gov. Mike Braun commits to join federal initiative to cover GLP-1 medications for obesity through Medicaid. (Photo by Niki Kelly/Indiana Capital Chronicle)Hoosiers insured through Medicaid will soon gain access to GLP-1 medications for obesity. Gov. Mike Braun on Thursday directed the Indiana Family and Social Services Administration, which administers Medicaid benefits to 1.9 million Hoosiers, to participate in a federal initiative to cover GLP…
thepampanews.com
Indiana Medicaid will cover GLP-1s for obesity
Gov. Mike Braun commits to join federal initiative to cover GLP-1 medications for obesity through Medicaid. (Photo by Niki Kelly/Indiana Capital Chronicle)Hoosiers insured through Medicaid will soon gain access to GLP-1 medications for obesity. Gov. Mike Braun on Thursday directed the Indiana Family and Social Services Administration, which administers Medicaid benefits to 1.9 million Hoosiers, to participate in a federal initiative to cover GLP…
Indiana Medicaid will cover GLP-1s for obesity - Seward Independent
Gov. Mike Braun commits to join federal initiative to cover GLP-1 medications for obesity through Medicaid. (Photo by Niki Kelly/Indiana Capital Chronicle)Hoosiers insured through Medicaid will soon gain access to GLP-1 medications for obesity. Gov. Mike Braun on Thursday directed the Indiana Family and Social Services Administration, which administers Medicaid benefits to 1.9 million Hoosiers, to participate in a federal initiative to cover GLP…
State Medicaid Program to Cover GLP-1 Treatments for Eligible Hoosiers
Source: Love Employee / Getty STATEWIDE — A state medicaid program will now cover GLP-1 treatments for eligible Hoosiers. On Thursday, Indiana Gov. Mike Braun announced that the Indiana Family and Social Services Administration (FSSA) will participate in the Center for Medicare and Medicaid Innovation’s BALANCE demonstration. This means the state will be expanding access to select GLP-1 medications for eligible Indiana Medicaid members. “Indiana…
Coverage Details
Bias Distribution
- 55% of the sources are Center
Factuality
To view factuality data please Upgrade to Premium
